Merck’s latest deal turns up the spotlight on immune system drugmakers
BioPharma Dive
APRIL 17, 2023
The buyout of Prometheus highlights pharmaceutical companies’ intense interest in medicines targeting inflammatory diseases, according to analysts.
Boehringer Ingelheim to lay off staff amid biosimilar challenges
BioPharma Dive
APRIL 5, 2024
The German pharmaceutical company is “streamlining” its custom-facing teams behind Cyltezo, a copycat version of AbbVie’s immune disease drug Humira.
Biosimilars 
62
62 Join 33,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Povetacicept by Alpine Immune Sciences for Systemic Lupus Erythematosus: Likelihood of Approval
Pharmaceutical Technology
MARCH 2, 2023
Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The drug candidate is an engineered B-cell modulator.
Immunity 40
40 
How global healthcare partners and Indian pharma companies are contributing to affordable medicines
Express Pharma
APRIL 16, 2024
Indian pharmaceutical companies play a crucial role in fulfilling global demand for critical vaccines, including those endorsed by the World Health Organization (WHO) for diseases (like Tetanus, Pertussis, Diphtheria, and Bacillus Calmette-Guerin), highlighting India’s indispensable contribution to global immunization efforts.
Vaccines 104
104 
NK cell immunotherapy: what’s next in clinical development?
European Pharmaceutical Review
DECEMBER 12, 2023
He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. We specialise in the development of new cutting-edge immunotherapies , based on the use of therapeutic antibodies capable of activating the immune system to fight cancer.
Immunity 105
105 
Chemo-free regimen demonstrates efficacy in NSCLC
European Pharmaceutical Review
SEPTEMBER 29, 2023
Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).
Innovation in immuno-oncology: Leading companies in cancer monoclonal antibody therapy
Pharmaceutical Technology
FEBRUARY 15, 2023
Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).
Immunity 104
104 
Top Performing Drugs of 2021: Proceeding the Series
PharmaShots
APRIL 25, 2023
Numerous pharmaceutical companies have developed and authorized vaccines to provide immunity against COVID-19. Despite the drenched market of covid products, many other drugs have set an impressive benchmark for pharmaceutical companies in 2021.
Will Novartis provide new oral option for chronic hives?
European Pharmaceutical Review
AUGUST 9, 2023
The pharmaceutical company announced that it plans to submit to global health authorities in 2024. appeared first on European Pharmaceutical Review. The REMIX data for Novartis’ novel BTK inhibitor will be presented at an upcoming medical meeting. There were 470 participants in the REMIX-1 study.
Immunity 69
69 
Incannex engages QPS for CannQuit and ReneCann
Pharmaceutical Technology
APRIL 17, 2023
Australian pharmaceutical company Incannex has appointed Quest Pharmaceutical Services (QPS) to advance CannQuit-N (Nicotine), CannQuit-O (Opioid) and Renecann Products in the USA and the European Union (EU). French company Eurofins Scientific is currently developing and manufacturing both products.
Immunity 52
52 
Exploring opportunity and unmet needs in busy ulcerative colitis space
Pharmaceutical Technology
SEPTEMBER 14, 2022
Most drugs available for the treatment of UC weaken patients’ immune systems, which puts them at higher risk of infection. Key opinion leaders (KOLs) interviewed by GlobalData have suggested that this group of patients would benefit from a greater number of treatment options that cause less systemic immune-related side effects.
Immunity 52
52 
Ex-Merck & Co scientist accused of stealing trade secrets could face jail
pharmaphorum
JANUARY 18, 2021
In a document outlining the charges against Shafat Quadri, of North Potomac, Maryland the US Department of Justice (DoJ) referred only to “one of the largest pharmaceutical companies in the world” based in New Jersey.
Innovation in immuno-oncology: Leading companies in tumour antibody serum compositions
Pharmaceutical Technology
MARCH 9, 2023
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.
Immunity 59
59 
India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other
NY Times
JANUARY 2, 2021
The approvals, which include a shot developed by Bharat Biotech, an Indian pharmaceutical company, begin a vast campaign to inoculate the hard-hit nation’s 1.3 billion people.
Vaccines 98
98 
Cancer vaccines: providing the edge in oncology
pharmaphorum
FEBRUARY 9, 2022
The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment. Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology. A broad front.
Vaccines 134
134 
CUE-102 by Cue Biopharma for Metastatic Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 26, 2023
Cue Biopharma overview Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse.
Immunity 40
40 
CUE-102 by Cue Biopharma for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Pharmaceutical Technology
FEBRUARY 26, 2023
Cue Biopharma overview Cue Biopharma operates as pharmaceutical company. The company develops biologic drugs for human immune system to treat cancers and autoimmune disorders. The company’s pipeline products include CUE-100 series to improve various tumor specific T cells Browse.
Immunity 40
40 
Innovation in biosimilars: Leading companies in neuro-degenerative receptor binding drug compositions
Pharmaceutical Technology
FEBRUARY 14, 2023
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. AC Immune and F. Hoffmann-La Roche are the other key patent filers in neuro-degenerative receptor binding drug compositions.
Biosimilars 98
98 
Leading innovators in monoclonal antibody drugs for cancer for the pharmaceutical industry
Pharmaceutical Technology
MARCH 9, 2023
Innovation S-curve for the pharmaceutical industry Monoclonal antibody drugs for cancer is a key innovation area in pharmaceutical Used to treat cancer, monoclonal antibodies are a type of targeted cancer therapy that use lab-created antibodies to find and kill specific cancer cells.
Immunity 52
52 
MP-0310 by Molecular Partners for Cervical Cancer: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.
MP-0310 by Molecular Partners for Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.
Inject the Vaccine Fan Fiction Directly Into My Veins
NY Times
APRIL 27, 2021
It feels very American to turn the vaccine rollout into a branding spectacle rooted in the worship of pharmaceutical companies.
Vaccines 62
62 
Developing a first-in-class small molecule drug for inflammatory disease
European Pharmaceutical Review
NOVEMBER 9, 2023
TNF-alpha is an immune modulating cytokine whose dysregulation can lead to prolonged inflammatory responses and is known to drive disease in a range of autoimmune and inflammatory disorders. MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system.
Drug Development 104
104 
Antony Blinken Says ‘We Have Fallen Short’ on Global Vaccine Distribution
NY Times
NOVEMBER 10, 2021
The Secretary of State called for rich countries, pharmaceutical companies and others to “step up.”.
Vaccines 52
52 
Big Pharma and the Covid Vaccines
NY Times
JANUARY 7, 2021
Readers discuss an Op-Ed that argued that pharmaceutical companies don’t deserve the public relations lift from the rapid vaccine development.
Vaccines 52
52 
Governments and pharma relationships and implications for antimicrobial resistance
Pharmaceutical Technology
AUGUST 1, 2022
AMR occurs when disease-causing bacteria become resistant or immune to the antibiotics used to treat them. For this, it will be necessary for governments to establish substantial incentive schemes to encourage pharmaceutical companies to invest more time, effort and money into antibiotic research.
Vaccines 93
93 
Could virtual reality become an essential tool for healthcare education?
pharmaphorum
JUNE 1, 2022
To try to improve health literacy, one study turned to VR to engage individuals and improve understanding of community immunity, or herd immunity, as it is also known. This has not escaped the notice of pharmaceutical companies looking to educate patients on topics, with which they may not have the most health literacy.
Vaccines 145
145 
Leading innovators in HIV peptides for the pharmaceutical industry
Pharmaceutical Technology
APRIL 18, 2023
HIV proteins or peptides are very immunogenic, and when utilised as experimental immunogens, they can elicit strong cellular and humoral immune reactions. A piece of an HIV protein, an epitope from an HIV protein, or a mixture of several HIV proteins or fragments of them can all act as the antigenic polypeptide and produce an immune response.
Mayo Clinic 59
59 
Data-crunching specialist CytoReason signs $110m Pfizer alliance
pharmaphorum
SEPTEMBER 20, 2022
The two companies have been talking to each other since 2017 and formally working together since 2019, when Pfizer started using CytoReason’s biological models in research aimed at developing new drugs for immune-mediated diseases and cancer immunotherapies.
The future of targeted alpha therapy development and manufacture
European Pharmaceutical Review
MARCH 7, 2024
Lastly, there is growing prominence and interest in radioligand therapeutics within major pharmaceutical companies, who are increasingly investing in this field, evident through recent acquisitions of Point Biopharma and RayzeBio. What makes targeted alpha therapies a promising new approach against cancer?
Innovation in immuno-oncology: Leading companies in monoclonal antibody conjugates for cancer treatment
Pharmaceutical Technology
MAY 8, 2023
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. Hoffmann-La Roche is a biotechnology company that develops drugs and diagnostics to treat major diseases.
Mayo Clinic 52
52 
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Retatrutide?
Pharmaceutical Technology
FEBRUARY 24, 2023
Eli Lilly and Co Overview Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly is headquartered in Indianapolis, Indiana, the US.
Diabetes 45
45 
Leading innovators in flavivirus vaccine components
Pharmaceutical Technology
FEBRUARY 15, 2023
The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response.
Vaccines 52
52 
Getting Quality Supplements
The Thyroid Pharmacist
NOVEMBER 29, 2023
The truth is that most supplement companies do not undergo the same scrutiny and testing that pharmaceutical products do, because many of the tests which are required of pharmaceutical companies are voluntary for supplement companies. We have 290 expiring in April 2025.)
GSK continues campaign for greater adult immunisation coverage
pharmaphorum
OCTOBER 21, 2022
Mukherjee explained that the human immune system becomes weaker as people age, which leads to a greater susceptibility to catching infectious diseases and also experiencing more acute cases when infected.
Vaccines 98
98 
Leading innovators in coronavirus vaccine components
Pharmaceutical Technology
FEBRUARY 15, 2023
Innovation S-curve for the pharmaceutical industry Coronavirus vaccine components is a key innovation area in pharmaceuticals Components used in vaccines include antigens, preservatives, stabilisers, surfactants, residuals, diluents, and adjuvants. The vaccine also contains other inactive ingredients such as cholesterol.
Vaccines 52
52 
Investment fuels AI-driven development of breakthrough genomic medicines
pharmaphorum
OCTOBER 12, 2022
Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”. Forging an AI-enabled path toward precision medicine.
Immunity 105
105 
Leading innovators in IgG gene expressing animal models for the pharmaceutical industry
Pharmaceutical Technology
FEBRUARY 15, 2023
Innovation S-curve for the pharmaceutical industry IgG gene expressing animal models is a key innovation area in the pharmaceutical industry IgG is the most abundant immunoglobulin found in the bloodstream and plays a major role in linking foreign particles to innate immune cells.
Immunity 52
52 
Innovation in immuno-oncology: Leading companies in oncolytic viral proteins
Pharmaceutical Technology
MAY 15, 2023
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. The company has an operational presence in the US and the UK (headquartered in Abingdon, Oxfordshire, UK).
The benefits of being a family-run pharma company
pharmaphorum
SEPTEMBER 22, 2021
Some pharmaceutical companies, including Chiesi, established emergency committees to build business continuity plans and contingencies to protect drug supply and worker safety. Despite COVID-19, we expanded the new business unit to 275 employees in more than 20 countries in just 18 months.
Immunity 111
111 
Country focus: China & APAC’s growing medical needs bring opportunities and challenges
pharmaphorum
JUNE 8, 2021
At the same time, lots of people with experience at multinational pharmaceutical companies have chosen to return home. All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Chemotherapy still accounted for 72.6%
Chemotherapy 105
105 
Digital innovation drives vaccine development
pharmaphorum
JANUARY 31, 2022
The digital transformation is allowing pharmaceutical companies to expand their drug discovery capabilities and accelerate drug development. As Shanaya says, some of the biggest developments have involved mRNA vaccines, “a completely different way to stimulate an immune response.”. Innovation at Pfizer.
Vaccines 97
97 
Investing in biologics excellence
pharmaphorum
MARCH 10, 2022
Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases. Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030.
Leading innovators in anti-viral antigen-based compositions for the pharmaceutical industry
Pharmaceutical Technology
MAY 8, 2023
Innovation S-curve for the pharmaceutical industry Anti-viral antigen-based compositions is a key innovation area in pharmaceuticals A viral antigen is a protein encoded by the viral genome that can be detected by a specific immunological response.
Vaccines 59
59 
Let's personalize your content